Search Within

Chrisann Kyi Kyi

  1. "Stuart Lichtman"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (5)
  2. Department of Medicine (5)
  3. Epidemiology and Biostatistics (5)
  4. GDMT, Medicine (5)
  5. Gynecologic Medicine Service (5)
  6. Gynecology Disease Management Team (5)

More Groups

People
  1. Alexia Iasonos (5)
  2. Carol Aghajanian (5)
  3. Claire Friedman (5)
  4. Qin Zhou (5)
  5. Roisin O'Cearbhaill (5)
  6. Stuart Lichtman (5)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2019 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. Gynecologic Oncology (1)
  3. Nature Medicine (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Elsevier Inc. (1)
  3. Nature Publishing Group (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save